Rationale and design of the EVOLVE Short DAPT Study to assess 3‐month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention
Sign Up to like & getrecommendations! Published in 2018 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.08.004
Abstract: Background While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet (P2Y12) inhibitor after percutaneous coronary intervention (PCI) reduces the risk of stent thrombosis (ST) and myocardial infarction (MI), it also increases bleeding. Newer… read more here.
Keywords: dapt; risk; evolve short; dapt study ... See more keywords
Design and Rationale of the XIENCE Short DAPT Clinical Program: an Assessment of the Safety of 3-month or 1-month DAPT in Patients at High Bleeding Risk Undergoing PCI with an Everolimus-Eluting Stent.
Sign Up to like & getrecommendations! Published in 2020 at "American heart journal"
DOI: 10.1016/j.ahj.2020.09.019
Abstract: Dual antiplatelet therapy (DAPT) is key for the prevention of recurrent ischemic events after percutaneous coronary intervention (PCI), however, it increases the risk of bleeding complications. While new generation drug-eluting stents have been shown superior… read more here.
Keywords: dapt; program; xience short; xience ... See more keywords